GLP-1 Peptide Atlas, by Delfa

CompletedPhase 3Results posted

A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Tirzepatide Monotherapy Compared With Placebo in Chinese Participants With Type 2 Diabetes

Lead sponsor

Eli Lilly and Company

Asset

Tirzepatide

Subcutaneous · GLP-1 / GIP dual

Listed sites

Recruiting sites

—

Enrollment

206

actual

Study population

Type 2 diabetes

Key I/E criteria

•BMI ≥23•HbA1c ≥7%

Primary endpoint

•HbA1c, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05963022

Org study ID18746

Secondary IDI8F-MC-GPIUEli Lilly and Company

Timeline

Milestones

Study first posted2023-07-27actual

Study start2023-08-21actual

Primary completion2024-10-09actual

Study completion2024-10-09actual

Last update posted2025-10-21actual

Results first posted2025-10-21actual

Assets

Investigational agents

Tirzepatide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Have Type 2 Diabetes

•Have HbA1c ≥7.0% (≥53 mmol/mol) to ≤9.5% (≤80 mmol/mol) despite diet and exercise treatment

•Are of stable weight 5%) during the 90 days preceding screening and agree not to initiate a diet and/or exercise program during the study with the intent of reducing body weight other than the lifestyle and dietary measures for diabetes treatment

•Have Body Mass Index (BMI) ≥23.0 kilogram per square meter (kg/m²)

Exclusion criteria

•Have Type 1 Diabetes

•Have a history of chronic or acute pancreatitis any time prior to study entry

•Are currently receiving treatment for diabetic retinopathy and/or macular edema

•Have a history of ketoacidosis or hyperosmolar state/coma

•Have a history of New York Heart Association Functional Classification IV congestive heart failure (CHF)

•Have acute or chronic hepatitis including a history of autoimmune hepatitis

•Use of insulin 1-year preceding screening and between screening and baseline; use of any antihyperglycemic medication 90 days preceding screening and between screening and baseline.

Endpoints (20)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Weight & body composition

8 endpoints

Secondary/registry result

Change From Baseline in Body Weight

Time frame:Baseline, Week 40

Body weight, absolute change (kg)

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), kilograms (kg)	95% CI
5 mg Tirzepatide	-6.1	—
10 mg Tirzepatide	-5.5	—
15 mg Tirzepatide	-8.7	—
Placebo	-1.3	—

LS Mean Difference-4.895% CI-6.7 – -2.9p<0.001ANCOVA

LS Mean Difference-4.295% CI-6.2 – -2.3p<0.001ANCOVA

LS Mean Difference-7.395% CI-9.3 – -5.4p<0.001ANCOVA

Secondary/registry result

Percentage of Participants Who Achieved Weight Loss of ≥5%

Time frame:Week 40

≥5% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (number), percentage of participants	95% CI
5 mg Tirzepatide	54.90	—
10 mg Tirzepatide	66.67	—
15 mg Tirzepatide	88.37	—
Placebo	7.41	—

Odds Ratio (OR)18.1995% CI5.27 – 62.73p<0.001Regression, Logistic

Odds Ratio (OR)30.9695% CI8.87 – 108.05p<0.001Regression, Logistic

Odds Ratio (OR)73.4295% CI19.36 – 278.40p<0.001Regression, Logistic

Secondary/registry result

Percentage of Participants Who Achieved Weight Loss of ≥10%

Time frame:Week 40

≥10% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (number), percentage of participants	95% CI
5 mg Tirzepatide	27.45	—
10 mg Tirzepatide	33.33	—
15 mg Tirzepatide	58.14	—
Placebo	0	—

Odds Ratio (OR)39.0495% CI2.29 – 664.36p0.011Regression, Logistic

Odds Ratio (OR)56.3495% CI3.34 – 949.59p0.005Regression, Logistic

Odds Ratio (OR)127.5295% CI7.58 – 2145.42p<0.001Regression, Logistic

Secondary/registry result

Percentage of Participants Who Achieved Weight Loss of ≥15%

Time frame:Week 40

≥15% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (number), percentage of participants	95% CI
5 mg Tirzepatide	9.80	—
10 mg Tirzepatide	13.33	—
15 mg Tirzepatide	37.21	—
Placebo	0	—

Odds Ratio (OR)13.8695% CI0.75 – 254.78p0.077Regression, Logistic

Odds Ratio (OR)15.6595% CI0.87 – 281.74p0.062Regression, Logistic

Odds Ratio (OR)66.6995% CI3.90 – 1140.13p0.004Regression, Logistic

Secondary/protocol endpoint

Change From Baseline in Body Weight

Time frame:Baseline, Week 40

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Percentage of Participants Who Achieved Weight Loss of ≥5%

Time frame:Week 40

≥5% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Percentage of Participants Who Achieved Weight Loss of ≥10%

Time frame:Week 40

≥10% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Percentage of Participants Who Achieved Weight Loss of ≥15%

Time frame:Week 40

≥15% weight-loss responders

threshold achievement, improvement

Glycemic / diabetes

12 endpoints

Primary/registry result

Change From Baseline in Hemoglobin A1c (HbA1c)

Time frame:Baseline, Week 40

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Posted result

Group	Value (least_squares_mean), percentage of HbA1c	95% CI
5 mg Tirzepatide	-2.19	—
10 mg Tirzepatide	-1.75	—
15 mg Tirzepatide	-2.03	—
Placebo	-0.77	—

LS Mean Difference-1.4295% CI-1.76 – -1.07p<0.001ANCOVA

LS Mean Difference-0.9895% CI-1.34 – -0.63p<0.001ANCOVA

LS Mean Difference-1.2695% CI-1.61 – -0.92p<0.001ANCOVA

Primary/protocol endpoint

Change From Baseline in Hemoglobin A1c (HbA1c)

Time frame:Baseline, Week 40

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/registry result

Percentage of Participants With HbA1c Target Values of <7.0% (<53 Millimole/Mole [mmol/Mol])

Time frame:Week 40

HbA1c <7.0% achievement

threshold achievement, improvement

LOINC 4548-4

Posted result

Group	Value (number), percentage of participants	95% CI
5 mg Tirzepatide	90.38	—
10 mg Tirzepatide	86.36	—
15 mg Tirzepatide	83.33	—
Placebo	38.30	—

Odds Ratio (OR)17.0495% CI5.62 – 51.73p<0.001Regression, Logistic

Odds Ratio (OR)7.5195% CI2.77 – 20.37p<0.001Regression, Logistic

Odds Ratio (OR)7.2495% CI2.74 – 19.14p<0.001Regression, Logistic

Secondary/registry result

Change From Baseline in Fasting Serum Glucose

Time frame:Baseline, Week 40

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Posted result

Group	Value (least_squares_mean), milligram per deciliter (mg/dL)	95% CI
5 mg Tirzepatide	-55.0	—
10 mg Tirzepatide	-54.8	—
15 mg Tirzepatide	-55.4	—
Placebo	-30.2	—

LS Mean Difference-24.895% CI-33.3 – -16.3p<0.001ANCOVA

LS Mean Difference-24.695% CI-33.2 – -15.9p<0.001ANCOVA

LS Mean Difference-25.295% CI-33.7 – -16.7p<0.001ANCOVA

Secondary/registry result

Percentage of Participants With HbA1c Target Values of ≤6.5% (≤48 mmol/Mol)

Time frame:Week 40

HbA1c <6.5% achievement

threshold achievement, improvement

LOINC 4548-4

Posted result

Group	Value (number), percentage of participants	95% CI
5 mg Tirzepatide	88.46	—
10 mg Tirzepatide	75.00	—
15 mg Tirzepatide	81.25	—
Placebo	23.40	—

Odds Ratio (OR)25.6195% CI8.70 – 75.36p<0.001Regression, Logistic

Odds Ratio (OR)7.2595% CI2.88 – 18.25p<0.001Regression, Logistic

Odds Ratio (OR)10.9595% CI4.23 – 28.34p<0.001Regression, Logistic

Secondary/registry result

Percentage of Participants With HbA1c Target Values of <5.7% (<39 mmol/Mol)

Time frame:Week 40

HbA1c <5.7% achievement

threshold achievement, improvement

LOINC 4548-4

Posted result

Group	Value (number), percentage of participants	95% CI
5 mg Tirzepatide	40.38	—
10 mg Tirzepatide	34.09	—
15 mg Tirzepatide	56.25	—
Placebo	0	—

Odds Ratio (OR)76.6295% CI4.40 – 1333.29p0.003Regression, Logistic

Odds Ratio (OR)49.3695% CI2.80 – 868.67p<0.001Regression, Logistic

Odds Ratio (OR)118.2295% CI6.80 – 2055.04p<0.001Regression, Logistic

Secondary/registry result

Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose Profiles (SMBG)

Time frame:Baseline, Week 40

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), milligram per deciliter (mg/dL)	95% CI
5 mg Tirzepatide	-78.4	—
10 mg Tirzepatide	-78.3	—
15 mg Tirzepatide	-80.8	—
Placebo	-33.9	—

LS Mean Difference-44.595% CI-57.5 – -31.5p<0.001Mixed Models Analysis

LS Mean Difference-44.395% CI-57.6 – -31.1p<0.001Mixed Models Analysis

LS Mean Difference-46.995% CI-60.1 – -33.7p<0.001Mixed Models Analysis

Secondary/protocol endpoint

Percentage of Participants With HbA1c Target Values of <7.0% (<53 Millimole/Mole [mmol/Mol])

Time frame:Week 40

HbA1c <7.0% achievement

threshold achievement, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change From Baseline in Fasting Serum Glucose

Time frame:Baseline, Week 40

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Percentage of Participants With HbA1c Target Values of ≤6.5% (≤48 mmol/Mol)

Time frame:Week 40

HbA1c <6.5% achievement

threshold achievement, improvement

LOINC 4548-4

Secondary/protocol endpoint

Percentage of Participants With HbA1c Target Values of <5.7% (<39 mmol/Mol)

Time frame:Week 40

HbA1c <5.7% achievement

threshold achievement, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose Profiles (SMBG)

Time frame:Baseline, Week 40

Postprandial glucose

change from baseline, improvement

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Yin Y, Ma J, Liu D, Duan W, Cheng Z, Jiang H, Zhang Y, Wu G, Zhuang H, Gu W, Mu Y. Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO). Med. 2026 Jun 15:101183. doi: 10.1016/j.medj.2026.101183. Online ahead of print.
PMID42296968via clinicaltrials gov reference derived

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.